RxDoctor Payments Data

Patrice Delafontaine, MD

Cardiovascular Disease · Columbia, MONPI 1063526523

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $8,572 of the $9,234 with a category attached, or 92.8%. Siemens Medical Solutions USA, Inc. accounts for 96.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $9,020 and has fallen 98.8% since, to $109 in 2023.

$9,234in general payments, 2019–2025

Across 19 payments — averaging $485.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$9K
  • Shockwave Medical, Inc$109
  • Novo Nordisk$91
  • Pfizer$81
  • Preventice Services, LLC$22
$128,879in research payments, 2019–2025

Across 20 payments — averaging $6443.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Johnson & Johnson$129K

What the payments were for

  • Travel & lodging$8,57293%
  • Food & beverage$6627%

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,234 in reported general payments places this provider in the 75th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$4,337
Medicare patients
15
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan13$21,704
EliquisApixaban12$20,425
JardianceEmpagliflozin12$19,762
Metoprolol Succinate35$357
Rosuvastatin Calcium24$271
Losartan Potassium14$140
Atorvastatin Calcium21$91
Amlodipine Besylate15$88
Hydrochlorothiazide13$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$81$20,42512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →